Celltrion s Humira Biosimilar approved and set for launch in Europe
Photo by: Celltrion/Facebook
Related Stories
Celltrion Healthcare will bring its parent company’s adalimumab biosimilar called Yuflyma to Europe next month. The company is in charge of Celltrion’s businesses overseas, and it will be launching the said biosimilar drug and start its sale in European countries.
The launch of Yuflyma
As per The Korea Herald, Celltrion will introduce Yuflyma in six European regions at first. A company official reportedly said that they will attempt to release the product in Spain this coming June, but this date could still change.